Pharma companies may be treading where doctors have been unwilling to go – meaningful pay-for-performance. Pharmaceutical companies are engaging in risk-sharing with payers, including governments and insurance companies.
According to Saturday’s New York Times, companies like Johnson & Johnson, GlaxoSmithKline, Biogen Idec and others are accepting reimbursement based on actual effectiveness of their drugs. This takes health outcomes one step further and provides compensation based on actual effectiveness of pharmaceutical products.
For an embattled pharmaceutical industry, this is a great way to demonstrate the value of its products!
Monday, July 16, 2007
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment